Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 15c; Offers FY23 Revenue Guidance

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.46), $0.15 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $95.3 million versus the consensus estimate of $91.4 million.

GUIDANCE:

Intra-Cellular Therapies sees FY2023 revenue of $430-455 million, versus the consensus of $448 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Pembina joins proposed 1M bbl/day Alberta-to-coast pipeline plan